MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY

被引：0
|
作者：
Neeraj, Agarwal [1 ]
Michael, T. Schweizer [1 ]
Elena, Castro [1 ]
Arun, A. Azad [1 ]
Daniel, J. George [1 ]
Jayeta, Chakrabarti [1 ]
Sujata, Narayanan [1 ]
Yiyun, Tang [1 ]
Karim, Fizazi [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst NCI CCC, Salt Lake City, UT USA
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2025年 / 43卷 / 03期
关键词：
D O I：
10.1016/j.urolonc.2024.12.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/ prednisone or enzalutamide
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D., I
    Nordquist, L. T.
    Wagner, V. J.
    Siegel, J.
    Trandafir, L.
    Sartor, O.
    ESMO OPEN, 2021, 6 (02)
  • [42] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
    Morris, Michael J.
    Rathkopf, Dana E.
    Novotny, William
    Gibbons, Jacqueline A.
    Peterson, Amy C.
    Khondker, Zakaria
    Ouatas, Taoufik
    Scher, Howard I.
    Fleming, Mark T.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3774 - 3781
  • [44] Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Salem, S.
    Komisarenko, M.
    Timilshina, N.
    Martin, L.
    Grewal, R.
    Alibhai, S.
    Finelli, A.
    CLINICAL ONCOLOGY, 2017, 29 (09) : 601 - 608
  • [45] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 142 - 148
  • [46] Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer
    Emamekhoo, Hamid
    Barata, Pedro C.
    Edwin, Natasha C.
    Woo, Kaitlin M.
    Grivas, Petros
    Garcia, Jorge A.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 429 - 436
  • [47] Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
    Antonarakis, Emmanuel S.
    Subudhi, Sumit K.
    Pieczonka, Christopher M.
    Karsh, Lawrence I.
    Quinn, David I.
    Hafron, Jason M.
    Wilfehrt, Helen M.
    Harmon, Matthew
    Sheikh, Nadeem A.
    Shore, Neal D.
    Petrylak, Daniel P.
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2426 - 2434
  • [48] A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy
    Templeton, Arnoud J.
    Omlin, Aurelius Gabriel
    Pezaro, Carmel Jo
    Kheoh, Thian San
    Leibowitz-Amit, Raya
    Vera-Badillo, Francisco Emilio
    Tannock, Ian
    Attard, Gerhardt
    Amir, Eitan
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [49] Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.
    Kassabian, Vahan
    Flanders, Scott
    Wilson, Samuel
    Brown, Bruce A.
    Song, Yan
    Yang, Hongbo
    Lechpammer, Stanislav
    Schultz, Neil M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Powles, Thomas
    Yuen, Kobe C.
    Gillessen, Silke
    Kadel, Edward E.
    Rathkopf, Dana
    Matsubara, Nobuaki
    Drake, Charles G.
    Fizazi, Karim
    Piulats, Josep M.
    Wysocki, Piotr J.
    Buchschacher, Gary L., Jr.
    Alekseev, Boris
    Mellado, Begona
    Karaszewska, Boguslawa
    Doss, Jennifer F.
    Rasuo, Grozdana
    Datye, Asim
    Mariathasan, Sanjeev
    Williams, Patrick
    Sweeney, Christopher J.
    NATURE MEDICINE, 2022, 28 (01) : 144 - +
12345